Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 12.02.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
12.02.Avon Protection - Unmasking its growth potential318Avon Protection's capital markets day highlighted its continued focus on medium-term margin expansion (targeting operating margin of 14-16%), concentrating on its core business of respirators and head...
► Artikel lesen
12.02.Custodian Property Income REIT - On track to meet dividend target317Custodian Property Income REIT (CREI) has released a trading update for the three months to 31 December 2023 (Q424). The quarterly DPS was fully covered by unaudited EPRA earnings and was in line with...
► Artikel lesen
12.02.Claranova - Guiding to strong H124 EBITDA growth458Claranova reported a small increase in H124 revenue on a constant currency (cc) basis, as good growth in Avanquest and myDevices offset lower revenue in the larger PlanetArt division. Management expects...
► Artikel lesen
12.02.GCP Infrastructure Investments - Key takeaways from capital markets day365GCP Infrastructure Investments (GCP) has a mature, diverse and operational portfolio of 51 UK infrastructure assets with a total asset value of £1.1bn and a net asset value (NAV) of £953m, two-thirds...
► Artikel lesen
12.02.Immix Biopharma - Updates galore: NXC-201 ODD (EU) and raise304Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid light chain amyloidosis (ALA), and pricing of its $15m...
► Artikel lesen
12.02.IRLAB Therapeutics - Timeline refresh with numerous inflection points297IRLAB has reported FY23 results and provided operational and regulatory updates, including an end-of-Phase II (EoP2) meeting with the FDA for mesdopetam and extended patent protection for pirepemat...
► Artikel lesen